Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in
essential hypertensive patients not adequately responsive to olmesartan
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Olmesartan Olmesartan Medoxomil Sacubitril and valsartan sodium hydrate drug combination